CYTOPOINT was shown to be safe when administered to laboratory Beagles at up to 5 times the label dose (10 mg/kg) monthly for 7 months. No treatment effects on clinical observations or clinical pathology were identified
Ongoing safety monitoring
Ongoing pharmacovigilance monitoring, beginning in July 2015, continues to show a safety profile similar to that seen in clinical trials
Indication: CYTOPOINT aids in the reduction of clinical signs associated with atopic dermatitis in dogs.
References: 1. Data on file, Study Report No. C961R-US-13-051, Zoetis Inc. 2. Data on file, Study Report No. C362N-US-13-042, Zoetis Inc.
This site is intended for U.S. Animal Healthcare Professionals. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.
The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.